Please ensure Javascript is enabled for purposes of website accessibility

Why Mylan N.V. Stock Is Soaring Today

By Keith Speights – Nov 6, 2018 at 11:58AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Better-than-expected Q3 earnings generated excitement for the drugmaker.

What happened

Shares of Mylan N.V. (MYL) are soaring today, up 16.4% as of 11:40 a.m. EST, after the drugmaker reported better-than-expected Q3 earnings following the market close on Monday. Mylan announced adjusted earnings per share (EPS) of $1.25, up 13.6% year over year and above analysts' consensus estimate of $1.19. 

So what

Anytime the narrative changes dramatically for a company, investors become excited. That appears to be what's happening for Mylan.

Dollar sign made up of multi-colored pills

Image source: Getty Images.

Only three months ago, Mylan slashed its full-year 2018 outlook because of significant problems in the U.S. market. Sales for the company's EpiPen auto-injector dropped significantly in the wake of generic competition. Mylan experienced problems at its Morgantown, West Virginia, manufacturing facility, with the U.S. Food and Drug Administration (FDA) uncovering numerous issues during a five-week inspection. And the company continued to run into a generally bleak pricing environment for generic drugs in the U.S.

Have all of these problems been resolved? Actually, no. Mylan's North American sales still fell 14% year over year in the third quarter. But Wall Street lowered expectations prior to the third quarter more than it probably should have. 

As is often the case, the story for Mylan wasn't as bad as some might have made it out to be. Despite challenges in the U.S., the drugmaker has been consistently strong in international markets, especially outside of Europe. 

Now what

The key for Mylan is to move past its problems in the U.S. and generate solid growth. One great way to do that is to achieve success with new products. CEO Heather Bresch noted in her Q3 comments that the company has launched close to 475 new products so far in 2018.

An important one for investors to watch is Hulio, Mylan's biosimilar to the world's best-selling drug, Humira. Mylan launched Hulio in Europe in October. Another key product to keep your eyes on is a generic version of another blockbuster drug, Advair. Mylan currently awaits an approval decision for the drug by the FDA. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.